41
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A mutation in the POT1 gene is responsible for cardiac angiosarcoma in TP53-negative Li–Fraumeni-like families

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Cardiac angiosarcoma (CAS) is a rare malignant tumour whose genetic basis is unknown. Here we show, by whole-exome sequencing of a TP53-negative Li–Fraumeni-like (LFL) family including CAS cases, that a missense variant (p.R117C) in POT1 ( protection of telomeres 1) gene is responsible for CAS. The same gene alteration is found in two other LFL families with CAS, supporting the causal effect of the identified mutation. We extend the analysis to TP53-negative LFL families with no CAS and find the same mutation in a breast AS family. The mutation is recently found once in 121,324 studied alleles in ExAC server but it is not described in any other database or found in 1,520 Spanish controls. In silico structural analysis suggests how the mutation disrupts POT1 structure. Functional and in vitro studies demonstrate that carriers of the mutation show reduced telomere-bound POT1 levels, abnormally long telomeres and increased telomere fragility.

          Abstract

          Genetic factors that cause cardiac angiosarcoma are unknown. Calvete et al. show that a missense mutation in protection of telomeres 1 (POT1) gene causes cardiac angiosarcoma by affecting the POT1 function and, consequently, telomere length and stability.

          Related collections

          Most cited references31

          • Record: found
          • Abstract: found
          • Article: not found

          Protein disorder prediction: implications for structural proteomics.

          A great challenge in the proteomics and structural genomics era is to predict protein structure and function, including identification of those proteins that are partially or wholly unstructured. Disordered regions in proteins often contain short linear peptide motifs (e.g., SH3 ligands and targeting signals) that are important for protein function. We present here DisEMBL, a computational tool for prediction of disordered/unstructured regions within a protein sequence. As no clear definition of disorder exists, we have developed parameters based on several alternative definitions and introduced a new one based on the concept of "hot loops," i.e., coils with high temperature factors. Avoiding potentially disordered segments in protein expression constructs can increase expression, foldability, and stability of the expressed protein. DisEMBL is thus useful for target selection and the design of constructs as needed for many biochemical studies, particularly structural biology and structural genomics projects. The tool is freely available via a web interface (http://dis.embl.de) and can be downloaded for use in large-scale studies.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            PredictProtein—an open resource for online prediction of protein structural and functional features

            PredictProtein is a meta-service for sequence analysis that has been predicting structural and functional features of proteins since 1992. Queried with a protein sequence it returns: multiple sequence alignments, predicted aspects of structure (secondary structure, solvent accessibility, transmembrane helices (TMSEG) and strands, coiled-coil regions, disulfide bonds and disordered regions) and function. The service incorporates analysis methods for the identification of functional regions (ConSurf), homology-based inference of Gene Ontology terms (metastudent), comprehensive subcellular localization prediction (LocTree3), protein–protein binding sites (ISIS2), protein–polynucleotide binding sites (SomeNA) and predictions of the effect of point mutations (non-synonymous SNPs) on protein function (SNAP2). Our goal has always been to develop a system optimized to meet the demands of experimentalists not highly experienced in bioinformatics. To this end, the PredictProtein results are presented as both text and a series of intuitive, interactive and visually appealing figures. The web server and sources are available at http://ppopen.rostlab.org.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Cardiac tumours: diagnosis and management.

              Primary cardiac tumours are rare, with an autopsy incidence ranging from 0.001% to 0.030%. Three-quarters of these tumours are benign and nearly half of the benign tumours are myxomas. Metastases to the heart are far more common than primary cardiac tumours. Primary cardiac tumours present with one or more of the symptoms of the classic triad of: cardiac symptoms and signs resulting from intracardiac obstruction; signs of systemic embolisation; and systemic or constitutional symptoms. They are diagnosed by use of transthoracic and transoesophageal echocardiograms, MRI, and CT scan. Whereas surgery is indicated in patients with benign tumours, systemic chemotherapy is indicated in those who have widespread or unresectable malignant disease, and chemotherapy and radiotherapy are usually combined in treatment of patients with primary cardiac lymphomas. The prognosis after surgery is usually excellent in the case of benign tumours but is unfortunately still limited in localised malignant diseases. Patients with sarcomas live for a mean of 3 months to 1 year, and those with lymphomas live up to 5 years if treated, but usually die within 1 month if untreated.
                Bookmark

                Author and article information

                Journal
                Nat Commun
                Nat Commun
                Nature Communications
                Nature Pub. Group
                2041-1723
                25 September 2015
                2015
                : 6
                : 8383
                Affiliations
                [1 ]Human Genetics Group, Spanish National Cancer Research Center (CNIO) , Melchor Fernandez Almagro 3, Madrid 28029, Spain
                [2 ]Center for Biomedical Network Research on Rare Diseases (CIBERER) , Madrid 28029, Spain
                [3 ]Telomeres and Telomerase Group, Spanish National Cancer Research Center (CNIO) , Madrid 28029, Spain
                [4 ]Department of Cardiology. Hospital Universitario Puerta de Hierro, Mahadahonda , Madrid 28222, Spain
                [5 ]Department of Cardiovascular Development and Repair, Centro Nacional de Investigaciones Cardiovasculares (CNIC) , Madrid 28029, Spain
                [6 ]Department of Pathology. Hospital Universitario Puerta de Hierro Majadahonda , Madrid 28222, Spain
                [7 ]Oncology Department, Clara Campal Comprehensive Cancer Center, Sanchinarro , Madrid 28050, Spain
                [8 ]Department of Experimental Models of Human Disease. Instituto Investigaciones Biomédicas (CSIC/UAM) , Madrid 28029, Spain
                [9 ]Bioinformatic Unit, Sistemas Genómicos , Paterna 46980, Spain
                [10 ]Medical Oncology Service, Hospital Universitario Lozano Blesa , Zaragoza 50009, Spain
                [11 ]Medical Oncology Service, Hospital General de Ciudad Real , Ciudad Real 13005, Spain
                [12 ]Familial Cancer Clinical Unit, Spanish National Cancer Research Center (CNIO) , Madrid 28029, Spain
                [13 ]Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL) , Barcelona 08908, Spain
                [14 ]Department of Physiological Sciences II, School of Medicine, University of Barcelona , Barcelona 08007, Spain
                [15 ]Institució Catalana de Recerca i Estudis Avançats (ICREA) , Barcelona 08010, Spain
                [16 ]Cytogenetics Unit, Spanish National Cancer Research Center (CNIO) , Madrid 28029, Spain
                [17 ]Genetics Department, Rouen University Hospital , Rouen 76000, France
                Author notes
                [*]

                These authors contributed equally to this work.

                [†]

                These authors jointly supervised this work.

                [‡]

                Present address: Department of Human Genetics, McGill University, Montreal, Québec, Canada QC H3A 0G4.

                Article
                ncomms9383
                10.1038/ncomms9383
                4598567
                26403419
                49063e47-7a0d-4795-923e-f8d1332c6e08
                Copyright © 2015, Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.

                This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

                History
                : 06 April 2015
                : 14 August 2015
                Categories
                Article

                Uncategorized
                Uncategorized

                Comments

                Comment on this article